Morgan Stanley Rubius Therapeutics, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.31 $1,967 - $4,357	-14,057 Reduced 18.42%	62,273 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $15,994 - $44,853	-34,770 Reduced 31.3%	76,330 $33,000
Q2 2022 Oct 27, 2022	SELL	$0.79 - $5.98 $127,693 - $966,589	-161,637 Reduced 59.26%	111,100 $94,000
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $127,693 - $966,589	-161,637 Reduced 59.26%	111,100 $94,000
Q1 2022 Oct 27, 2022	BUY	$4.25 - $10.4 $686,957 - $1.68 Million	161,637 Added 145.49%	272,737 $1.5 Million
Q1 2022 May 13, 2022	BUY	$4.25 - $10.4 $19,783 - $48,412	4,655 Added 1.74%	272,737 $1.5 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $1.39 Million - $2.54 Million	143,359 Added 114.94%	268,082 $2.6 Million
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $2.2 Million - $3.23 Million	124,723 New	124,723 $2.23 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.